How RWE360 Supported A Mid Sized Pharma To Enter A New Therapeutic Area

Industry

Biotechnology

Challenge

This company was entering a rare disease therapeutic area where traditional clinical development approaches would have lead to unfeasibly long development timlines & reduced probabilities of succsess

Results

Using RWD360 the company was able to rapidly identify every potential data source globally that could be used to generate an external control arm for both regulatory and internal purposes.

Key Product

RWE360

Months Time Saved

1000+

Data Sources Identified

9.6x

ROI

$5M

Cost Savings

Working with Inovia Bio has accelerated our approach to evidence generation and clinical development. RWE360 hasn't just shown us what data we can potentially use to support our program, but also given us a KOL engagement and patient recruitment strategy

S Carole

VP Clinical Development

Using RWD360 we were able to quickly identify who the opinion leaders in the disease space where and quickly set out collaborative strategies

N Randers

Director Medical Affairs

picture of an office, with a few people working at desks

Entering A New Indication

The partner in this case study is a mid sized pharmaceutical company with an established oncology pipeline. Through previous collaborations the company had aquired an asset which was likely to show promisse in a rare, non malignent therapeutic area

The Challenge

The partner in this case study is an established mid-sized pharmaceutical company with a established pipeline and experience in Oncology. Through a collaboration, the company had acquired rights into a promising early asset, that while fitting into the company's portfolio strategy was in a new therapeutic area.

As the company were in early clinical development, they needed to understand what options were available to accelerate their timelines and proactivly support their evidence generation strategy.

The Solution

In search of a solution, the company discovered RWD360, a cutting-edge real-time systematic real-world evidence data landscaping tool. After considering several options including using traditional CROs, RWD360 was chosen due to its speed, accuracy and ease of use. The company quickly integreated RWD360 into their clinical development and evidence generation workflows, which allowed them to navigate the challanges of a novel therapeutic area with ease.

Using RWD360 allowed the company in this case study to have a complete, regulatory grade landscape of every RWD asset relevant to their disease as well as a landscape of KOLs complete in less than a week

The Results

The partner in this case study saved 7 months in their clinical development process and achieved a return on investment of 9.4X. They were able to rapidly build natural history and external control studies to support their development strategy as well build a robust medical affairs strategy based on a real time, live mapping of the disease landscape.

RWD360 as a platform is bundled with the expertise of the Inovia Bio medical team ensuring that partners not only have a complete understanding of every RWD asset globally but also expert support to exploit that data into high impact outcomes. All without ever receiving a single change order